Date published: 2026-5-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

EBP Activators

EBP, or Emopamil Binding Protein, activators comprise a select group of chemical compounds that function to specifically enhance the activity of EBP, a protein encoded by the EBP gene. EBP is an essential component of the mevalonate pathway, a critical metabolic route responsible for the synthesis of sterols, including cholesterol. Activators of EBP typically work by engaging with the protein at a molecular level to stabilize its active form or to enhance its interaction with substrates or cofactors required for its enzymatic activity. These compounds can include small molecules that bind to the active site of EBP, altering its conformation in a way that promotes its activity. Some EBP activators may also function by binding to allosteric sites, which are distinct from the enzyme's active site, resulting in a conformational change that increases the protein's catalytic efficiency. By influencing EBP's activity, these activators play a significant role in modulating the mevalonate pathway and, consequently, the biosynthesis of various sterols and isoprenoids.

The biochemical activation mechanisms by which EBP activators exert their effects are highly specific and tailored to the structure and function of the EBP enzyme. These activators may enhance the binding affinity of EBP for its substrates, thereby increasing the rate of reaction it catalyzes. Others might act by protecting EBP from degradative processes, ensuring a more stable and prolonged activity within the cellular environment. Some activators are designed to mimic the natural substrates of EBP, thereby providing a more efficient pathway for the enzyme to catalyze its intended reaction. By directly affecting the enzymatic action of EBP, activators ensure that the rate of sterol synthesis is maintained at a level conducive to the needs of the cell. The precise activity of each activator is a result of careful molecular design that takes into account the three-dimensional structure of EBP, ensuring that the activation is as effective as possible without altering other cellular functions.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Cholesterol

57-88-5sc-202539C
sc-202539E
sc-202539A
sc-202539B
sc-202539D
sc-202539
5 g
5 kg
100 g
250 g
1 kg
25 g
$27.00
$2809.00
$129.00
$210.00
$583.00
$88.00
11
(1)

Cholesterol is a direct substrate for EBP, which is a δ(8)-δ(7) sterol isomerase in the cholesterol biosynthesis pathway. The binding and conversion of cholesterol by EBP enhance its enzymatic activity.

25-Hydroxycholesterol

2140-46-7sc-214091B
sc-214091
sc-214091A
sc-214091C
5 mg
10 mg
25 mg
100 mg
$53.00
$91.00
$169.00
$474.00
8
(2)

25-Hydroxycholesterol serves as a ligand for LXRs affecting SREBP processing and indirectly influencing EBP by modulating cholesterol levels and metabolism.

Simvastatin

79902-63-9sc-200829
sc-200829A
sc-200829B
sc-200829C
50 mg
250 mg
1 g
5 g
$31.00
$89.00
$135.00
$443.00
13
(1)

Simvastatin is an HMG-CoA reductase inhibitor that can lead to compensatory upregulation of the cholesterol biosynthesis pathway, thereby potentially enhancing the functional activity of EBP.

Geranylgeraniol

24034-73-9sc-200858
sc-200858A
20 mg
100 mg
$162.00
$474.00
14
(1)

Geranylgeraniol can upregulate the mevalonate pathway, which is upstream of cholesterol synthesis, potentially increasing the availability of substrates for EBP.

Lovastatin

75330-75-5sc-200850
sc-200850A
sc-200850B
5 mg
25 mg
100 mg
$29.00
$90.00
$339.00
12
(1)

As with simvastatin, lovastatin is an HMG-CoA reductase inhibitor that can indirectly enhance the activity of EBP through feedback mechanisms in cholesterol biosynthesis.

Atorvastatin

134523-00-5sc-337542A
sc-337542
50 mg
100 mg
$257.00
$505.00
9
(1)

Atorvastatin is another HMG-CoA reductase inhibitor that, through feedback mechanisms, may increase the flow of substrates through the cholesterol biosynthesis pathway, thus enhancing EBP activity.

Farnesol

4602-84-0sc-204748
sc-204748A
50 ml
100 ml
$281.00
$374.00
2
(1)

As an intermediate in the mevalonate pathway, farnesol can upregulate the synthesis of cholesterol precursors, indirectly enhancing the enzymatic activity of EBP.

Squalene

111-02-4sc-281155
sc-281155A
sc-281155B
10 ml
100 ml
500 ml
$49.00
$92.00
$215.00
1
(0)

As a precursor in the cholesterol biosynthesis pathway, squalene's presence may indirectly signal for the enhanced activity of downstream enzymes like EBP.

Lanosterol

79-63-0sc-215229
sc-215229A
1 mg
5 mg
$105.00
$350.00
2
(0)

Lanosterol is metabolized by EBP in the cholesterol biosynthesis pathway. Its conversion to more downstream sterols is facilitated by EBP, enhancing its enzymatic function.